Does alendronate improve bone mineral density in patients with ra treated with glucocorticoids?

Does alendronate improve bone mineral density in patients with ra treated with glucocorticoids?

Play all audios:

Loading...

Access through your institution Buy or subscribe boxed-textLems WF _ et al_. (2006) Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial. _Osteoporos Int_ 17: 716–723 BACKGROUND This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 12 print issues and online access $209.00 per year only $17.42 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support REFERENCES * Van Staa TP _ et al_. (2003) Bone density threshold and other predictors of vertebral fractures in patients receiving oral glucocorticoid therapy. _Arthritis Rheum_ 48: 3224–3229 Article  CAS  Google Scholar  * Lane NE _ et al_. (2006) Glucocorticoid-treated mice have localized changes in trabecular bone material properties and osteocyte lacunar size that are not observed in placebo-treated or estrogen-deficient mice. _J Bone Miner Res_ 21: 466–476 Article  CAS  Google Scholar  * Balooch G _ et al_. (2005) Risedronate maintains bone matrix mechanical properties and mineralization in a glucocorticoid-induced osteoporosis mouse and human study. Presented at the American Society for Mineral and Bone Research Annual Meeting, 23–27 September 2005, Nashville, Tennessee Download references ACKNOWLEDGEMENTS The synopsis was written by Jasmine Farsarakis, Associate Editor, Nature Clinical Practice. AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * the Director and Endowed Professor of the Aging Center, Medicine and Rheumatology, at the University of California at Davis Medical Center in Sacramento, CA, USA Nancy E Lane Authors * Nancy E Lane View author publications You can also search for this author inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence to Nancy E Lane. ETHICS DECLARATIONS COMPETING INTERESTS The author declares no competing financial interests. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Lane, N. Does alendronate improve bone mineral density in patients with RA treated with glucocorticoids?. _Nat Rev Rheumatol_ 2, 412–413 (2006). https://doi.org/10.1038/ncprheum0248 Download citation * Received: 20 April 2006 * Accepted: 15 June 2006 * Issue Date: August 2006 * DOI: https://doi.org/10.1038/ncprheum0248 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative

Access through your institution Buy or subscribe boxed-textLems WF _ et al_. (2006) Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with


rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial. _Osteoporos Int_ 17: 716–723 BACKGROUND This is a preview of


subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 12 print issues and online access $209.00 per year only


$17.42 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout


ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support REFERENCES * Van Staa TP _ et al_. (2003) Bone density threshold and


other predictors of vertebral fractures in patients receiving oral glucocorticoid therapy. _Arthritis Rheum_ 48: 3224–3229 Article  CAS  Google Scholar  * Lane NE _ et al_. (2006)


Glucocorticoid-treated mice have localized changes in trabecular bone material properties and osteocyte lacunar size that are not observed in placebo-treated or estrogen-deficient mice. _J


Bone Miner Res_ 21: 466–476 Article  CAS  Google Scholar  * Balooch G _ et al_. (2005) Risedronate maintains bone matrix mechanical properties and mineralization in a glucocorticoid-induced


osteoporosis mouse and human study. Presented at the American Society for Mineral and Bone Research Annual Meeting, 23–27 September 2005, Nashville, Tennessee Download references


ACKNOWLEDGEMENTS The synopsis was written by Jasmine Farsarakis, Associate Editor, Nature Clinical Practice. AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * the Director and Endowed Professor


of the Aging Center, Medicine and Rheumatology, at the University of California at Davis Medical Center in Sacramento, CA, USA Nancy E Lane Authors * Nancy E Lane View author publications


You can also search for this author inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence to Nancy E Lane. ETHICS DECLARATIONS COMPETING INTERESTS The author declares no competing


financial interests. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Lane, N. Does alendronate improve bone mineral density in patients with RA treated


with glucocorticoids?. _Nat Rev Rheumatol_ 2, 412–413 (2006). https://doi.org/10.1038/ncprheum0248 Download citation * Received: 20 April 2006 * Accepted: 15 June 2006 * Issue Date: August


2006 * DOI: https://doi.org/10.1038/ncprheum0248 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is


not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative